Cipla LtdNSE: CIPLA

Press Release Aug 12 2021

· Issued by Cipla Ltd

Filed with NSE · · 3 pages · English

Summary by 6ix AI

Cipla Ltd has issued a press release announcing the receipt of final approval for its generic version of Durezol from the US FDA. The product, Difluprednate Ophthalmic Emulsion, is indicated for treating inflammation and pain associated with ocular surgery and endogenous anterior uveitis.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Cipla Limited has informed the Exchange regarding a press release dated August 12, 2021, titled "Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol�� (Difluprednate Ophthalmic Emulsion 0.05%)".

Cipla Ltd on 6ix

Earlier from Cipla

Later from Cipla

All Cipla news releases